Literature DB >> 10208435

Deregulation of the proto-oncogene c-myc through t(8;22) translocation in Burkitt's lymphoma.

A Gerbitz1, J Mautner, C Geltinger, K Hörtnagel, B Christoph, H Asenbauer, G Klobeck, A Polack, G W Bornkamm.   

Abstract

In Burkitt's lymphoma (BL) cells the proto-oncogene c-myc is juxtaposed to one of the immunoglobulin (Ig) loci on chromosomes 2, 14, or 22. The c-myc gene becomes transcriptionally activated as a consequence of the chromosomal translocation and shows preferential usage of promoter P1 over P2, a phenomenon referred to as promoter shift. In order to define the responsible regulatory elements within the Ig lambda locus, we studied the effect of the human Ig lambda enhancer (HuE lambda) on c-myc expression after stable transfection into BL cells. A 12 kb genomic fragment encompassing HuE lambda, but not HuE lambda alone, strongly activated c-myc expression and induced the promoter shift. To identify additional elements involved in c-myc deregulation, we mapped DNaseI hypersensitive sites within the 12 kb lambda fragment on the construct. Besides one hypersensitive site corresponding to HuE lambda, three additional sites were detected. Two of these elements displayed enhancer activity after transient transfection. The third element did not activate c-myc transcription, but was required for full c-myc activation and promoter shift. Deletion analyses of the c-myc promoter identified the immediate promoter region as sufficient for activation by the Ig lambda. locus, but also revealed that induction of the promoter shift requires additional upstream elements.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10208435     DOI: 10.1038/sj.onc.1202468

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  17 in total

1.  MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.

Authors:  Martin S Staege; Steven P Lee; Teresa Frisan; Josef Mautner; Siegfried Scholz; Alexander Pajic; Alan B Rickinson; Maria G Masucci; Axel Polack; Georg W Bornkamm
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-26       Impact factor: 11.205

2.  A new 3'RR regulatory role during lymphomagenesis.

Authors:  Alexis Saintamand; Faten Saad; Yves Denizot
Journal:  Cell Cycle       Date:  2015-04-30       Impact factor: 4.534

3.  Disruption of HLA class II antigen presentation in Burkitt lymphoma: implication of a 47,000 MW acid labile protein in CD4+ T-cell recognition.

Authors:  Jason M God; Dan Zhao; Christine A Cameron; Shereen Amria; Jennifer R Bethard; Azizul Haque
Journal:  Immunology       Date:  2014-07       Impact factor: 7.397

4.  The IgG Fc receptor, FcgammaRIIB, is a target for deregulation by chromosomal translocation in malignant lymphoma.

Authors:  M B Callanan; P Le Baccon; P Mossuz; S Duley; C Bastard; R Hamoudi; M J Dyer; G Klobeck; R Rimokh; J J Sotto; D Leroux
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

5.  Elevation of c-MYC disrupts HLA class II-mediated immune recognition of human B cell tumors.

Authors:  Jason M God; Christine Cameron; Janette Figueroa; Shereen Amria; Azim Hossain; Bettina Kempkes; Georg W Bornkamm; Robert K Stuart; Janice S Blum; Azizul Haque
Journal:  J Immunol       Date:  2015-01-16       Impact factor: 5.422

6.  Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis.

Authors:  R Bultema; R Longnecker; M Swanson-Mungerson
Journal:  Oncogene       Date:  2009-02-02       Impact factor: 9.867

7.  Somatic hypermutation of the B cell receptor genes B29 (Igbeta, CD79b) and mb1 (Igalpha, CD79a).

Authors:  Melinda S Gordon; Cindy M Kanegai; Jeanette R Doerr; Randolph Wall
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-21       Impact factor: 11.205

8.  Burkitt lymphoma: pathogenesis and immune evasion.

Authors:  Jason M God; Azizul Haque
Journal:  J Oncol       Date:  2010-10-05       Impact factor: 4.375

9.  HLA class II defects in Burkitt lymphoma: bryostatin-1-induced 17 kDa protein restores CD4+ T-cell recognition.

Authors:  Azim Hossain; Jason M God; Faisal F Y Radwan; Shereen Amria; Dan Zhao; Jennifer R Bethard; Azizul Haque
Journal:  Clin Dev Immunol       Date:  2011-11-28

10.  Molecular profiling of aggressive lymphomas.

Authors:  Maura Rossi; Maria Antonella Laginestra; Anna Gazzola; Maria Rosaria Sapienza; Stefano A Pileri; Pier Paolo Piccaluga
Journal:  Adv Hematol       Date:  2011-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.